Takeda Pharmaceutical Receives FDA Fast Track Designation for TAK-242, Investigational Compound for Severe Sepsis.Tokyo, Japan, July 29, 2005 - (JCNN JCNN Japan Corporate News Network ) - Takeda Pharmaceutical announced on July 27 that one of its US affiliates, Takeda Global Research & Development Center of Illinois, has received fast track designation by the US Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for TAK-242, its investigational compound designed for the treatment of severe sepsis. TAK-242 is a compound that suppresses the production of inflammatory mediators including cytokine by the signal transduction mediated by Toll-like receptor (TLR TLR Trailer TLR Toll Like Receptor (immunological research) TLR Temple (University) Law Review TLR Twin Lens Reflex TLR Texas Law Review TLR The Last Resort (gaming clan) 4). Based on the results of clinical trials conducted in the Japan, EU and the US, the company plans to launch a global phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the in August, with consent from both FDA and the Pharmaceuticals and Medical Devices Agency. Source: JCN http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion